Cheng Yi Pharma(SH:603811) Xin Lang Cai Jing·2025-08-27 03:10Core Insights - Chengyi Pharmaceutical (603811.SH) reported a total revenue of 417 million yuan for the first half of 2025, an increase of 60.88 million yuan compared to the same period last year, marking a 17.11% year-on-year growth [1] - The net profit attributable to shareholders reached 112 million yuan, ranking 41st among disclosed peers, with an increase of 35.96 million yuan, reflecting a 47.03% year-on-year rise [1] - The net cash inflow from operating activities was 141 million yuan, ranking 36th among peers, with an increase of 75.17 million yuan, representing a 113.74% year-on-year growth [1] Financial Ratios - The latest debt-to-asset ratio stands at 23.88%, ranking 39th among disclosed peers, a decrease of 8.92 percentage points compared to the same period last year [3] - The latest gross profit margin is 69.78%, ranking 27th among peers, with an increase of 0.81 percentage points from the previous quarter and 0.07 percentage points year-on-year [3] - The latest return on equity (ROE) is 8.76%, ranking 14th among peers, with an increase of 2.40 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.35 yuan, ranking 30th among peers, with an increase of 0.12 yuan, reflecting a 52.17% year-on-year growth [3] - The latest total asset turnover ratio is 0.24 times, ranking 38th among peers, with an increase of 0.05 times year-on-year, marking a 26.18% rise [3] - The latest inventory turnover ratio is 1.06 times, with an increase of 0.18 times year-on-year, representing a 19.96% growth [3] Shareholder Structure - The number of shareholders is 15,700, with the top ten shareholders holding 132 million shares, accounting for 40.30% of the total share capital [3] - The largest shareholder is Yan Yiyi, holding 23.58% of the shares [3]